Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Imfinzi | durvalumab | Biliary tract cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Dupixent | dupilumab | atopic dermatitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Pluvicto | lutetium vipivotide tetraxetan | Metastatic castration-resistant prostate cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| TBC | abaloparatide | Osteoporosis, postmenopausal women | Withdrawn | |||
| Lynparza | olaparib | gBRCAm, HER2-negative high-risk early breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| TBC | tirzepatide | Diabetes mellitus, type 2 | Cancelled | |||
| Rylaze | crisantaspase recombinant | Acute lymphoblastic leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lumakras | sotorasib | KRAS G12C-mutated advanced NSCLC | Do not reimburse | Active | ||
| Empaveli | pegcetacoplan | Paroxysmal nocturnal hemoglobinuria | Reimburse with clinical criteria and/or conditions | Complete | ||
| TBC | ferumoxytol | Iron deficiency anemia | Withdrawn |
Last Updated : May 11, 2024